Impacts of PEGylation on the gene and oligonucleotide delivery system

Authors

  • Yutaka Ikeda,

    1. Department of Materials Sciences, Graduate School of Pure and Applied Sciences, University of Tsukuba, Ibaraki, Japan
    Search for more papers by this author
  • Yukio Nagasaki

    Corresponding author
    1. Department of Materials Sciences, Graduate School of Pure and Applied Sciences, University of Tsukuba, Ibaraki, Japan
    2. Master's School of Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan
    3. Satellite Laboratory, International Center for Materials Nanoarchitectonics (WPI-MANA), National Institute of Materials Science (NIMS), Ibaraki, Japan
    Search for more papers by this author

ABSTRACT

Poly(ethylene glycol) (PEG) is the most widely used polymer and also the gold standard in the field of drug delivery. Therapeutic oligonucleotides, for example, are modified with PEG at the terminus to increases nuclease resistance and the circulating half-lives. The surface of nanoparticle such as micelle and liposome has been also modified with PEG. At present, one PEGylated therapeutic oligonucleotide has been approved for the market and several more PEGylated products including oligonucleotide and liposome are being tested in clinical settings. This review summarizes the methods and effects of PEGylation on gene delivery. © 2013 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2014, 131, 40293.

Ancillary